Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Definitions

• the present invention relates generally to the delivery of pharmaceutical agents from the blood stream to the human brain and other organs or tissues that express the human insulin receptor. More particularly, the present invention involves the development of "humanized" monoclonal antibodies (MAb) that may be attached to pharmaceutical agents to form compounds that are able to readily bind to the human insulin receptor (HIR). The compounds are able to cross the human blood brain barrier (BBB) by way of insulin receptors located on the brain capillary endothelium. Once across the BBB, the humanized monoclonal antibody/pharmaceutical agent compounds are also capable of undergoing receptor mediated endocytosis into brain cells via insulin receptors located on the brain cells.
• MAb monoclonal antibodies
• HIR human insulin receptor
• the BBB is a system-wide membrane barrier that prevents the brain uptake of circulating drugs, protein therapeutics, antisense drugs, and gene medicines.
• Drugs or genes can be delivered to the human brain for the treatment of serious brain disease either (a) by injecting the drug or gene directly into the brain, thus bypassing the BBB, or (b) by injecting the drug or gene into the bloodstream so that the drug or gene enters the brain via the transvascular route across the BBB.
• intra-cerebral administration of the drug it is necessary to drill a hole in the head and perform a procedure called craniotomy.
• HIR MAb 83-14 is a murine MAb that binds to the human insulin receptor (HIR). This binding triggers transport across the BBB of MAb 83-14 (Pardridge et al, 1995), and any drug or gene payload attached to the MAb (Wu et al., 1997).
• HIR human insulin receptor
• HIRMAb 83-14 has been shown to rapidly undergo transport across the BBB of a living Rhesus monkey, and to bind avidly to isolated human brain capillaries, which are the anatomical substrate of the human BBB (see Pardridge et al., 1995). In either case, the activity of the HIRMAb 83-14 with respect to binding and transport at the primate or human BBB is more than 10-fold greater than the binding or transport of other peptidomimetic MAb's that may target other BBB receptors such as the transferrin receptor (Pardridge, 1997). To date, HIRMAb 83-14 is the most active BBB transport vector known (Pardridge, 1997).
• HIRMAb 83-14 has proven to be a very useful agent for the delivery of drugs to the primate brain in vivo, and would also be highly active for brain drug or gene delivery to the brain in humans. [0007] HIRMAb 83-14 cannot be used in humans because this mouse protein will be immunogenic. Genetically engineered forms of HIRMAb 83-14 might be used in humans in either the form of a chimeric antibody or a genetically engineered "humanized" HIRMAb. However, in order to perform the genetic engineering and production of either a chimeric or a humanized antibody, it is necessary to first clone the variable region of the antibody heavy chain (NH) and the variable region of the antibody light chain (NL).
• NH antibody heavy chain
• NL variable region of the antibody light chain
• HIRMAb 83-14 may lose biological activity following the humanization (Pichla et al., 1997). Therefore, it is uncertain as to whether the murine HIRMAb can be humanized with retention of biological activity.
• a chimeric form of the HIRMAb 83-14 has been genetically engineered, and the chimeric antibody binds to the HIR and is transported into the primate brain (Coloma et al., 2000). However, a chimeric antibody retains the entire mouse FR for both the NH and the NL, and because of this, chimeric antibodies are still immunogenic in humans (Bruggemann et al., 1989). In contrast to the chimeric antibody, a humanized antibody would use the human FR amino acid sequences for both the NH and the NL and retain only the murine amino acids for the 3 complementarity determining regions (CDRs) of the NH and 3 CDRs of the NL.
• CDRs complementarity determining regions
• the murine HIRMAb 83-14 antibody can be humanized to provide a biologically active humanized insulin receptor (HIR) antibody that may be used in combination with drugs and diagnostic agents to treat human beings in vivo.
• the HIR antibody may be conjugated to the drug or diagnostic agent using avidin-biotin conjugation or the HIR antibody/drug combination may be prepared as a fusion protein using genetic engineering techniques.
• the HIR antibody is especially well suited for delivering neuropharmaceutical agents to the human brain across the BBB.
• the humanized character of the HIR antibody significantly reduces immunogenic reactions in humans.
• the humanized murine antibody of the present invention is capable of binding to the HIR and includes a heavy chain (HC) of amino acids and a light chain (LC) of amino acids which both include variable and constant regions.
• the variable regions of the HC and LC include complementarity determining regions (CDRs) that are interspersed between framework regions (FRs).
• the HC includes a first CDR located at the amino end of the variable region, a third CDR located at the carboxyl end of the HC variable region and a second CDR located between said first and third CDRs.
• the amino acid sequences for the first CDR, the second CDR, and the third CDR are SEQ. ID. NOS. 31 , 33 and 35, respectively, and combined equivalents thereof.
• the HC framework regions include a first FR located adjacent to the amino end of the first CDR, a second FR located between said first and second CDRs, a third FR located between said second and third CDRs and a fourth FR located adjacent to the carboxyl end of said third CDR.
• the four FRs of the HC are humanized such that the overall antibody retains biological activity with respect to the HIR and is not immunogenic in humans.
• the LC also includes a first CDR located at the amino end of the variable region, a third CDR located at the carboxyl end of the variable region and a second CDR located between said first and third CDRs.
• the amino acid sequences for the first CDR, the second CDR, and the third CDR are SEQ. ID. NOS. 38, 40, and 42, respectively, and combined equivalents thereof.
• the LC framework regions include a first FR located adjacent to the amino end of said first CDR, a second FR located between said first and second CDRs, a third FR located between said second and third CDRs and a fourth FR located adjacent to the carboxyl end of said third CDR.
• the four FRs of the LC are humanized such that the overall antibody retains biological activity with respect to the HIR and has minimal immunogenicity in humans.
• the constant regions of the murine antibody are also modified to minimize immunogenicity in humans.
• the murine HC constant region is replaced with the HC constant region from a human immunoglobulin such as IgGl .
• the murine LC constant region is replaced with a constant region from the LC of a human immunoglobulin such as a kappa (K) LC constant region. Replacement of the murine HC and LC constant regions with human constant regions was found to not adversely affect the biological activity of the humanized antibody with respect to HIR binding.
• the present invention not only covers the humanized murine antibodies themselves, but also covers pharmaceutical compositions that are composed of the humanized antibody linked to a drug or diagnostic agent.
• the humanized antibody is effective in delivering the drug or diagnostic agent to the HIR in vivo to provide transport across the BBB and/or endocytosis into cells via the HIR.
• the compositions are especially well suited for intra venous (iv) injection into humans for delivery of neuropharmaceutical agents to the brain.
• FIG. 1 shows the nucleotide sequence for the murine NH (SEQ. ID. NO. 1) and murine NL (SEQ. ID. NO. 2) and deduced amino acid sequence of the murine NH (SEQ. ID. NO. 3) and the murine NL (SEQ. ID. NO. 4), which shows the 3 framework (FR) regions and the 4 complementarity determining regions (CDRs) of both the heavy chain (HC) and the light chain (LC) of the 83-14 murine HIRMAb.
• FR framework
• CDRs complementarity determining regions
• amino acids denoted by an asterisk (*) were confirmed by amino acid sequencing of either the intact murine LC or tryptic peptides of the intact murine HC; for amino acid sequencing, the intact murine HC or LC were purified from gels following purification of the intact murine IgG from the hybridoma conditioned medium.
• FIGS. 2A and 2B graphically show the results of a radio-receptor assay on isolated human brain capillaries that were obtained with a mechanical homogenization procedure from human autopsy brain. These capillaries were incubated with [ 125 I]-labeled chimeric HIRMAb (Coloma et al., 2000) (FIG. 2A) or [ 125 I]-version 5 humanized HIRMAb (FIG. 2B). The data show that both antibodies bind equally well to human brain capillaries, which form the anatomical basis of the BBB in humans.
• FIG. 3 shows the brain scan of a Rhesus monkey treated with a humanized monoclonal antibody in accordance with the present invention.
• the [ 125 I]-labeled version 5 HIRMAb was injected intravenously in an anesthetized rhesus monkey, and the animal was euthanized 120 minutes later.
• the brain was rapidly removed and cut into coronal hemispheric slabs, which were immediately frozen.
• Cryostat sections (20 ⁇ m) were cut and exposed to x-ray film.
• the film was scanned to yield the image shown in FIG. 3. This image shows the clear demarcations between the gray matter and white matter of the primate brain. Owing to the higher vascular density in gray matter, there is a greater uptake of the humanized HIRMAb, relative to white matter.
• FIG. 4 shows a comparison of the amino acid sequence for the 3 FRs and 3 CDRs of both the heavy chain and the light chain for the following: (a) the version 5 humanized HIRMAb, (v) the original murine 83-14 HIRMAb, and (c) the NH of the B43 human IgG or the VL of the REI human IgG.
• FIG. 5 shows the amino acid sequence of a fusion protein of human ⁇ -L- iduronidase (IDUA) (SEQ. ID. NO. 48), which is fused to the carboxyl terminus of the heavy chain (HC) of the humanized monoclonal antibody to the human insulin receptor (HIRMAb).
• the HC is comprised of a variable region (VH) and a constant region (CH); the CH is further comprised of 3 sub-regions, CHI (SEQ. ID. NO. 44), CH2 (SEQ. ID. NO. 45), and CH3 (SEQ. ID NO. 46); the CHI and CH2 regions are connected by a 12 amino acid hinge region (SEQ. ID. NO. 47).
• the amino acid sequence shown for the CH is well known in existing databases and co ⁇ esponds to the CH sequence of human IgGl . There is a single N-linked glycosylation site on the asparagine (N) residue within the CH2 region of the CH, and there are 6 potential N-linked glycosylation sites within the IDUA sequence, as indicated by the underline.
• the present invention involves the humanization of the murine monoclonal antibody identified as MAb 83-14 so that it can be used in vivo in humans.
• MAb 83-14 has a high affinity for the human insulin receptor at the human or rhesus monkey blood-brain barrier (Pardridge, et al. 1995) and is a candidate for use as a Trojan horse to transport neuropharmaceutical agents across the BBB.
• the term "pharmaceutical agents” is intended to include any drug, gene or chemical that is used to treat or diagnose disease in humans.
• the term “neuropharmaceutical agent” covers pharmaceutical agents that are used to treat brain disease.
• the present humanized antibody Trojan horses are especially well suited for transporting neuropharmaceutical agents from the blood stream to the brain across the BBB.
• the complete amino acid sequence for the variable region of the HC and LC of murine Mab 83-14 was determined as described in Example 1.
• the nucleotide sequence for the gene that expresses the murine VH (SEQ. ID. NO. 1) and the murine VL (SEQ. ID. NO. 2) is set forth in FIG. 1.
• the amino acid sequence for the murine VH (SEQ. ID. NO. 3) and murine VL (SEQ. ID. NO. 4) is also set forth in FIG 1.
• the amino acid sequences for the variable regions of the murine MAb 83-14 VH and VL are also set forth in FIG. 4 (SEQ. ID. NOS. 3 AND 4, respectively).
• the humanized murine antibodies of the present invention are prepared by modifying the amino acid sequences of the variable regions of the murine antibody to more closely resemble human antibody without destroying the ability of the antibody to strongly bind to the HIR.
• the humanized antibody includes constant regions that also correspond to human antibody.
• the humanized murine antibodies include a heavy chain of amino acids (HC) that is composed of a constant region (CH) and a variable region (VH).
• the variable region of the HC has an amino end and a carboxyl end and includes three CDRs interspersed between four FRs.
• the first CDR (CDR1) is located towards the amino end of the VH with the third CDR (CDR3) being located towards the carboxyl end of the HC.
• the amino acid sequences for murine MAb 83-14 HC CDR1, CDR2, and CDR3 are set forth in SEQ. ID. NOS. 31, 33 and 35, respectively.
• the humanized antibodies have HC CDRs with amino acid sequences that are identical to SEQ. ID. NOS. 31 , 33 and 35.
• the humanized antibodies may include CDRs in the HC that have amino acid sequences which are "individually equivalent” to SEQ. ID. NOS. 31, 33 and 35.
• "Individually equivalent” amino acid sequences are those that have at least 75 percent sequence identity and which do not adversely affect the binding of the antibody to the HIR.
• individually equivalent amino acid sequences will have at least 85 percent sequence identity with SEQ. ID. NOS. 31, 33 or 35. Even more preferred are individually equivalent amino acid sequences having at least 95 percent sequence identity.
• the three VH CDR amino acid sequences may also be viewed as a combined group of amino acid sequences (VH CDR1, VH CDR2 and VH CDR3).
• the present invention also covers equivalents of the combined group of VH CDR sequences.
• Such “combined equivalents” are those that have at least 75 percent sequence identity with the combined amino acid sequences SEQ. ID. NOS. 31, 32 and 35 and which do not adversely affect the binding of the antibody to the HIR.
• combined equivalent amino acid sequences will have at least 85 percent sequence identity with the combined sequences found in SEQ. ID. NOS. 31,33 and 35. Even more prefe ⁇ ed are combined equivalent amino acid sequences that have at least 95 percent sequence identity with the combined amino acid sequences (SEQ. ID. NOS. 31, 33 and 35).
• VH CDR amino acid sequences meet both the individual equivalency and combined equivalency requirements set forth above.
• the individual equivalency requirements are waived provided that the combined equivalency requirements are met.
• VH CDR3 SEQ. ID. NO. 35
• VH CDR3 is only 4 amino acids long. If two amino acids are changed, then the individual sequence identity is only 50% which is below the 75% floor for individual equivalence set forth above.
• the humanized murine antibodies also include a light chain (LC) of amino acids that is composed of a constant region (CL) and a variable region (VL).
• the variable region of the LC has an amino end and a carboxyl end and includes three CDRs interspersed between four FRs.
• the first CDR (CDR1) is located towards the amino end of the VL with the third CDR (CDR3) being located towards the carboxyl end of the VL.
• the amino acid sequences for murine MAb 83-14 LC CDR1, CDR2, and CDR3 are set forth in SEQ. ID. NOS. 38, 40 and 42, respectively. Since the VL CDRs are also important for antibody binding to the HIR, it is prefe ⁇ ed that the humanized antibodies have LC CDRs with amino acid sequences that are identical to SEQ. ID. NOS. 38, 40 and 42. However, the humanized antibodies may include CDRs in the VL that have amino acid sequences which are "individually equivalent" to SEQ. ID. NOS. 38, 40 or 42. "Individually equivalent" amino acid sequences are those that have at least 75 percent sequence identity and which do not adversely affect the binding of the antibody to the HIR.
• individually equivalent amino acid sequences will have at least 85 percent sequence identity with SEQ. ID. NOS. 38, 40 or 42. Even more prefe ⁇ ed are individually equivalent amino acid sequences having at least 95 percent sequence identity.
• the three VL CDR amino acid sequences may also be viewed as a combined group of amino acid sequences (VL CDR1, VL CDR2 and VL CDR3).
• the present invention also covers equivalents of the combined group of VL CDR sequences.
• Such “combined equivalents” are those that have at least 75 percent sequence identity with the combined amino acid sequences SEQ. ID. NOS. 38, 40 and 42 and which do not adversely affect the binding of the antibody to the HIR.
• combined equivalent amino acid sequences will have at least 85 percent sequence identity with the combined sequences found in SEQ. ID. NOS. 38, 40 and 42. Even more prefe ⁇ ed are combined equivalent amino acid sequences that have at least 95 percent sequence identity with the combined amino acid sequences (SEQ. ID. NOS. 38, 40 and 42).
• VL CDR amino acid sequences meet both the individual equivalency and combined equivalency requirements set forth above.
• the individual equivalency requirements are waived provided that the combined equivalency requirements are met.
• VH CDR3 SEQ. ID. NO. 42
• VH CDR3 is only 9 amino acids long. If three amino acids are changed, then the individual sequence identity is only 66% which is below the 75% floor for individual equivalence set forth above.
• the first framework region (FRl) of the VH is located at the amino end of the humanized antibody.
• the fourth framework region (FR4) is located towards the carboxyl end of the humanized antibody.
• Exemplary prefe ⁇ ed amino acid sequences for the humanized VH FRl, FR2, FR3 and FR4 are set forth in SEQ. ID. NOS. 30, 32, 34 and 36, respectively, and these prefe ⁇ ed sequences co ⁇ espond to version 5 humanized HIRMAb (Table 3).
• the amino acid sequence for FR2 (SEQ. ID. NO. 32) is identical to the amino acid sequence of murine MAb 83-14 VH FR2 or the human IgG, B43 (See FIG. 4).
• the amino acid sequences for VH FRl and FR4 (SEQ. ID. NOS. 30 and 36) co ⁇ espond to the B43 human antibody framework regions that have amino acid sequences that differ from murine MAb 83-14 (FIG. 4).
• the amino acid sequences for the VH FR3 (SEQ. ID. No. 34) of the version 5 humanized HIRMAb co ⁇ esponds to the VH FR3 of the murine 83-14 antibody (Table 3).
• Suitable alternate or equivalent FRs include those that have at least 70 percent individual sequence identity with SEQ. ID. NOS. 30, 32, 34 or 36 and do not destroy the resulting antibodies ability to bind the HIR.
• the alternate FRs will have at least 80 percent sequence identity with the prefe ⁇ ed VH FR that is being replaced. Even more prefe ⁇ ed are alternate FRs that have at least 90 percent sequence identity with the prefe ⁇ ed VH FR that is being replaced.
• the four VH FR amino acid sequences may also be viewed as a combined group of amino acid sequences (VH FRl, VH FR2, VH FR3 and VH FR4).
• the present invention also covers alternates or equivalents of the combined group of VH FR sequences.
• Such "combined equivalents" are those that have at least 70 percent sequence identity with the combined amino acid sequences SEQ. ID. NOS. 30, 32, 34 and 36 and which do not adversely affect the binding of the antibody to the HIR.
• combined equivalent amino acid sequences will have at least 80 percent sequence identity with the combined sequences found in SEQ. ID. NOS. 30, 32, 34 and 36. Even more prefe ⁇ ed are combined equivalent amino acid sequences that have at least 90 percent sequence identity with the combined amino acid sequences (SEQ. ID. NOS. 30, 32, 34 and 36).
• the first framework region (FRl) of the LC is located at the amino end of the VL of the humanized antibody.
• the fourth framework region (FR4) is located towards the carboxyl end of the VL of the humanized antibody.
• Exemplary prefe ⁇ ed amino acid sequences for the humanized VL FRl, FR2, FR3 and FR4 are set forth in SEQ. ID. NOS. 37, 39, 41 and 43, respectively.
• the amino acid sequences for VL FRl, FR2, FR3 and FR4 (SEQ. ID. NOS. 37, 39, 41 and 43) co ⁇ espond to the REI human antibody framework regions that have amino acid sequences that differ from murine MAb 83-14 (See FIG. 4).
• Suitable alternate or equivalent FRs include those that have at least 70 percent sequence identity with SEQ. ID. NOS. 37, 39, 41 and 43 and do not destroy the resulting antibodies ability to bind the HIR.
• the equivalent or alternate FRs will have at least 80 percent sequence identity with the prefe ⁇ ed VL FR that is being replaced. Even more prefe ⁇ ed are alternate FRs that have at least 90 percent sequence identity with the prefe ⁇ ed VL FR that is being replaced.
• the four VL FR amino acid sequences may also be viewed as a combined group of amino acid sequences (VL FRl, VL FR2, VL FR3 and VL FR4).
• the present invention also covers alternates or equivalents of the combined group of VL FR sequences.
• Such "combined equivalents" are those that have at least 70 percent sequence identity with the combined amino acid sequences SEQ. ID. NOS. 37, 39, 41 and 43 and which do not adversely affect the binding of the antibody to the HIR.
• combined equivalent amino acid sequences will have at least 80 percent sequence identity with the combined sequences found in SEQ. ID. NOS. 37, 39, 41 and 43.
• Even more prefe ⁇ ed are combined equivalent amino acid sequences that have at least 90 percent sequence identity with the combined amino acid sequences (SEQ. ID. NOS. 37, 39, 41 and 43).
• Version 5 is a prefe ⁇ ed humanized antibody in accordance with the present invention.
• the amino acid sequences for the VH and VL of Version 5 are set forth in SEQ. ID. NOS. 5 and 6, respectively.
• the preparation and identification of Version 5 is set forth in more detail in Example 2, Table 3 and FIG. 4.
• the amino acid sequences for the VH FRs of Version 5 co ⁇ espond to the prefe ⁇ ed VH FR sequences set forth above (SEQ. ID. NOS. 30, 32, 34 and 36).
• the amino acid sequences for the VL FRs of Version 5 co ⁇ espond to the prefe ⁇ ed VL FR sequences set forth above (SEQ. ID. NOS. 37, 39, 41, 43).
• VH and VL FRs of Version 5 are a prefe ⁇ ed example of VH and VL LC FRs that have been "humanized”. "Humanized” means that the four framework regions in either the HC or LC have been matched as closely as possible with the FRs from a human antibody (HAb) without destroying the ability of the resulting antibody to bind the HIR.
• the model human antibody used for the HC is the B43 antibody
• the model human antibody used for the LC is the REI antibody
• both the B43 and REI antibody sequences are well known and available in public databases.
• the HC or LC FRs are humanized, it is possible that one or more of the FRs will not co ⁇ espond identically with the chosen HAb template and may retain identity or similarity to the murine antibody.
• the degree to which murine amino acid sequences are left in the humanized FRs should be kept as low as possible in order to reduce the possibility of an immunogenic reaction in humans.
• FRs that have been humanized are set forth in Example 2 and Table 3. Framework regions from human antibodies that co ⁇ espond closely to the FRs of murine MAb 84-13 are chosen. The human FRs are then substituted into the MAb 84-13 in place of the murine FRs. The resulting antibody is then tested. The FRs, as a group, are only considered to be humanized if the modified antibody still binds strongly to the HIR receptor and has reduced immunogenicity in humans. If the first test is not successful, then the human FRs are modified slightly and the resulting antibody tested. Exemplary human antibodies that have HC FRs that may be used to humanize the HC FRs of MAb 84-13 include B43 human IgG (SEQ.
• human antibodies that have LC FRs that may be used to humanize the LC FRs of MAb 84-13 include human REI antibody (SEQ. ID. NO. 13), which is deposited in Genbank (accession number 1WTLB), and other human IgG molecules with a VL homologous to the murine 83-14 VL may be found by searching public databases, such as the Kabat Database of immunoglobulin sequences.
• the HC and LC should each include a constant region. Any number of different human antibody constant regions may be incorporated into the humanized antibody provided that they do not destroy the ability of the antibody to bind the HIR.
• Suitable human antibody HC constant regions include human IgGl, IgG2, IgG3, or IgG4.
• the prefe ⁇ ed HC constant region is human IgGl.
• Suitable human antibody LC constant regions include kappa (K) or lambda. Human K LC constant regions are prefe ⁇ ed.
• the humanized antibody may be used in the same manner as any of the other antibody targeting agents (Trojan Horses) that have previously been used to deliver genes, drugs and diagnostic agents to cells by accessing the HIR.
• the humanized antibody is typically linked to a drug or diagnostic compound (pharmaceutical agent) and combined with a suitable pharmaceutical ca ⁇ ier and administered intravenously (iv).
• a suitable pharmaceutical ca ⁇ ier and administered intravenously iv.
• the drug/humanized antibody complex could also be administered subcutaneously, intra-muscularly, intra-nasally, intra- thecally, or orally.
• the humanized antibody may be linked to the pharmaceutical agent.
• the humanized antibody may be fused to either avidin or streptavidin and conjugated to a pharmaceutical agent that has been mono- biotinylated in accordance with known procedures that use the avidin-biotin linkage to conjugate antibody Trojan Horses and pharmaceutical agents together.
• the humanized antibody and pharmaceutical agent may be expressed as a single fusion protein using known genetic engineering procedures.
• Exemplary pharmaceutical agents to which the humanized antibody may be linked include small molecules, recombinant proteins, synthetic peptides, antisense agents or nanocontainers for gene delivery.
• Exemplary recombinant proteins include basic f ⁇ broblast growth factor (bFGF), human ⁇ -L-iduronidase (IDUA), or other neurotrophins, such as brain derived neurotrophic factor, or other lysosomal enzymes.
• bFGF basic f ⁇ broblast growth factor
• IDUA human ⁇ -L-iduronidase
• neurotrophins such as brain derived neurotrophic factor, or other lysosomal enzymes.
• Trojan Horses such as the present humanized antibody, for transporting bFGF across the BBB is described in a co-pending United States Patent Application (UC Case 2002-094-1, Attorney Docket 0180-0027) that is owned by the same assignee as the present application and which was filed on the same day as the present application)
• the humanized antibody is linked to a pharmaceutical agent, it is administered to the patient in the same manner as other known conjugates or fusion proteins.
• the particular dose or treatment regimen will vary widely depending upon the pharmaceutical agent being delivered and the condition being treated.
• the prefe ⁇ ed route of administration is intravenous (iv).
• Suitable carriers include saline or water buffered with acetate, phosphate, TRIS or a variety of other buffers, with or without low concentrations of mild detergents, such as one from the Tween series of detergents.
• the humanized antibody/pharmaceutical agent Trojan horse compound is preferably used to deliver neuropharmaceutical agents across the BBB. However, the humanized Trojan horse may also be used to deliver pharmaceutical agents, in general, to any organ or tissue that carries the HIR.
• RNA was isolated from the 83-14 hybridoma cell line (Soos et al, 1986), and used to produce complementary DNA (cDNA) with reverse transcriptase.
• the cDNA was used with polymerase chain reaction (PCR) amplification of either the 83-14 VH or 83-14 VL gene using oligodeoxynucleotide (ODN) primers that specifically amplify the VH and VL of murine antibody genes, and similar methods are well known (Li et al., 1999).
• ODN oligodeoxynucleotide
• the PCR products were isolated from 1% agarose gels and the expected 0.4 Kb VH and VL gene products were isolated.
• the VH and VL gene fragments were sequentially subcloned into a bacterial expression plasmid so as to encode a single chain Fv (ScFv) antibody.
• the ScFv expression plasmid was then used to transform E. Coli.
• EXAMPLE 2 Iterative humanization of the 83-14 HIRMAb Version 1 through Version 5 [0043] Humanization of the 83-14 MAb was performed by CDR/FR grafting wherein the mouse FRs in the 83-14 MAb are replaced by suitable human FR regions in the variable regions of both the LC and HC.
• the Kabat database was screened using the Match program. Either the murine 83-14 VH or the VL amino acid sequence was compared with human IgG VH or human K light chain VL databases. Using the minimal mismatch possible, several human IgG molecules were identified that contained FR amino sequences highly homologous to the amino acid sequences of the murine 83-14 VH and VL.
• the framework regions of the B43 human IgGl heavy chain and the REI human light chain were finally selected for CDR/FR grafting of the murine 83-14 HIRMAb.
• 3'-PRC PRIMER REV 5'CATGCTAGCAGAGACGGTGACTGTG-3' (SEQ. ID. NO. 29)
• the PCR was performed in a total volume of 100 ⁇ L containing 5 pmole each of 6 overlapping ODNs, nucleotides, and Taq and Taq extender DNA polymerases.
• the humanized VH and VL genes were individually ligated in a bacterial expression plasmid and E. coli was transformed.
• Several clones were isolated, individually sequenced, and clones containing no PCR- introduced sequence e ⁇ ors were subsequently produced.
• the humanized VH insert was released from the bacterial expression plasmid with restriction endonucleases and ligated into eukaryotic expression vectors described previously (Coloma et al, 1992; U.S. Patent No. 5,624,659). A similar procedure was performed for the humanized VL synthetic gene. Myeloma cells were transfected with the humanized light chain gene, and this cell line was subsequently transfected with version 1 of the humanized heavy chain gene (Table 3). The transfected myeloma cells were screened in a 96-well ELISA to identify clones secreting intact human IgG. After multiple attempts, no cell lines producing human IgG could be identified.
• HC artificial gene which contained HC FR amino acids derived from a different human IgG sequence, that of the B43 human IgG (Bejcek et al, 1995), and this yielded version 2 of the humanized HIRMAb (Table 3).
• the version 2 humanized HIRMAb was not secreted by the transfected myeloma cell. Both versions 1 and 2 contain the same HC signal peptide (Table 3), which is derived from Rechavi et al (1983).
• the signal peptide sequence was changed to that used for production of the chimeric HIRMAb (Coloma et al, 2000), and the sequence of this signal peptide is given in Table 3. Versions 2 and 3 of the humanized HIRMAb differed only with respect to the signal peptide (Table 3). 04/050016
• Version 4a contained the murine FRl and the humanized FR2, FR3, and FR4; version 4b contained the murine FR 3, and FR4 and the humanized FRl and FR2 (Table 3). Both versions 4a and 4b were secreted, although version 4b was more active than version 4a. These findings indicated amino acids within either FR3 or FR4 were responsible for the lack of secretion of the humanized HIRMAb.
• the human and murine FR4 differed by only 1 amino acid (Table 3); therefore, the sequence of FR4 was altered by site-directed mutagenesis to co ⁇ espond to the human sequence, and this version was designated version 5 (Table 3).
• the version 5 HIRMAb co ⁇ esponded to the original CDR-grated antibody sequence with substitution of the human sequence in FR3 of the VH with the original murine sequence for the FR3 in the VH.
• Version 1 was designed using the FRs of the human 25C1C1 IgG heavy chain (HC) variable region (VH). Version 1 did not produce secreted hlgG from the transfected myeloma cells despite high abundance of the HC mRNA determined by Northern blot analysis.
• HC human 25C1C1 IgG heavy chain
• Version 2 was re-designed using the FRs of the human B43 IgG HC variable region.
• the peptide signal #1 (MDWTWRVLCLLAVAPGAHS) (SEQ. ID. NO. 49)in versions 1 and 2 was replaced by signal peptide #2 (MGWSWVMLFLLSVTAGKGL) (SEQ. ID. NO. 50) in version 3.
• the FRs and CDRs in version 2 and 3 are identical.
• the signal peptide #2 was used for versions 4a, 4b and 5.
• Verson 4a has human FRs 2, 3 and 4 and murine FRl.
• Version 4b has human FRs 1 and 2, and murine FRs 3 and 4
• Version 5 was produced using the human FRs 1, 2 and 4 and the murine FR3.
• Versions 4a, 4b and 5 produced secreted hlgG, whereas version 1 , 2, and 3 did not secrete IgG.
• version 5 contains fewer murine framework amino acid substitutions and is prefe ⁇ ed.
• the version 5 form of the protein was secreted intact from the transfected myeloma lines.
• the secreted version 5 humanized HIRMAb was purified by protein A affinity chromatography and the affinity of this antibody for the HIR was tested with an immunoradiometric assay (IRMA), which used [ 125 I]-labeled murine 83-14 MAb as the ligand as described previously (Coloma et al, 2000). These results showed that the affinity of the antibody for the HIR was retained.
• IRMA immunoradiometric assay
• the antigen was the extracellular domain of the HIR, which was produced from transfected CHO cells and purified by lectin affinity chromatography of CHO cell conditioned medium.
• the dissociation constant (K D ) of the murine and Version 5 humanized 83-14 HIRMAb was 2.7 ⁇ 0.4 nM and 3.7 ⁇ 0.4 nM, respectively.
• the humanized Version 5 HIRMAb was radiolabelled with 125-Iodine and injected intravenously into the adult Rhesus monkey. The animal was sacrificed 2 hours later and the brain was removed and frozen. Cryostat sections (20 micron) were cut and applied to X-ray film. Scanning of the film yielded an image of the primate brain uptake of the humanized HIRMAb (FIG. 3). The white matter and gray matter tracts of the primate brain are clearly delineated, with a greater uptake in the gray matter as compared with the white matter.
• IDUA ⁇ -L-iduronidase
• MPS mucopolysaccharidosis
• ERT enzyme replacement therapy
• the enzyme could be delivered across the human BBB following peripheral administration providing the enzyme is attached to a molecular Trojan horse such as the humanized HIRMAb.
• the IDUA may be attached to the humanized HIRMAb with avidin-biotin technology.
• the IDUA enzyme is mono-biotinylated in parallel with the production of a fusion protein of the humanized HIRMAb and avidin.
• the IDUA could be attached to the humanized HIRMAb not with avidin-biotin technology, but with genetic engineering that avoids the need for biotinylation or the use of foreign proteins such as avidin.
• the gene encoding for IDUA is fused to the region of the humanized HIRMAb heavy chain or light chain gene co ⁇ esponding to the amino or carboxyl terminus of the HIRMAb heavy or light chain protein.
• the HIRMAb/IDUA fusion protein is mass produced for purification and manufacturing.
• the amino acid sequence and general structure of a typical MAb/IDUA fusion protein is shown in FIG. 5 (SEQ. ID. NO. 48).
• the enzyme is fused to the carboxy terminus of the heavy chain (HC) of the humanized HIRMAb.
• the amino acid sequence for the IDUA shown in FIG. 5 is that of the mature, processed enzyme.
• the enzyme could be fused to the amino terminus of the HIRMAb HC or the amino or carboxyl termini of the humanized HIRMAb light chain (LC).
• one or more amino acids within the IDUA sequence could be modified with retention of the biological activity of the enzyme.
• Fusion proteins of lysosomal enzymes and antibodies have been prepared and these fusion proteins retain biological activity (Haisma et al, 1998).
• the fusion gene encoding the fusion protein can be inserted in one of several commercially available permanent expression vectors, such as pCEP4, and cell lines can be permanently transfected and selected with hygromycin or other selection agents.
• the conditioned medium may be concentrated for purification of the recombinant humanized HIRMAb/IDUA fusion protein.
• Myeloma cells (NSO) were transfected with a plasmid encoding the either the humanized HIRMAb light chain or "su ⁇ ogate light chain", which was an anti- dansyl MAb light chain (Shin and Morrison, 1990).
• the anti-dansyl light chain is derived from the anti-dansyl IgG, where dansyl is a common hapten used in antibody generation.
• Both the myeloma line transfected with the humanized HIRMAb light chain, and the myleoma line transfected with the su ⁇ ogate light chain were subsequently transfected with a plasmid encoding the heavy chain of the chimeric HIRMAb.
• the reactivity of these chimeric antibodies with the soluble extracellular domain (ECD) of the HIR was determined by ELISA.
• the HIR ECD was purified by lectin affinity chromatography of the conditioned medium of CHO cells transfected with the HIR ECD as described previously (Coloma et al, 2000).
• the murine 83-14 HIRMAb was used as a positive control and mouse IgG2a was used as a negative control.
• the negative control produced negligible ELISA signals; the standard curve with the murine 83- 14 MAb gave a linear increase in absorbance that reached saturation at 1 ⁇ g/ml murine 83-14 MAb.
• the immune reaction in the ELISA was quantified with a spectrophotometer and maximum absorbance at 405 nm (A405) in this assay was 0.9. All isolated myeloma clones secreting the chimeric HIRMAb heavy chain/humanized HIRMAb light chain IgG were positive in the HIR ECD ELISA with immuno-reactive levels that maximized the standard curve. In addition, the myeloma clones secreting the chimeric HIRMAb HC/dansyl LC IgG also produced positive signals in the HIR ECD ELISA, and the A405 levels were approximately 50% of the A405 levels obtained with the chimeric HIRMAb heavy chain/humanized HIRMAb light chain IgG.
• the LC is considered to be "compatible" with the HC if the LC can be combined with the HC and not destroy the ability of the resulting antibody to bind to the HIR. In additition, the LC must be human or sufficiently humanized so that any immunogenic reaction in humans is minimized. Routine experimentation can be used to determine whether a selected human or humanized LC sequence is compatible with the HC. [0060] Having thus described exemplary embodiments of the present invention, it should be noted by those skilled in the art that the within disclosures are exemplary only and that various other alternatives, adaptations and modifications may be made within the scope of the present invention. Accordingly, the present invention is not limited to the above prefe ⁇ ed embodiments and examples, but is only limited by the following claims.
• Haisma, J.J. et al (2000) Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human ⁇ -glucuronidase for antibody-directed enzyme prodrug therapy. Blood. 92: 184-190.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Animal Behavior & Ethology (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Endocrinology (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Cell Biology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Neurosurgery (AREA)
• Peptides Or Proteins (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Enzymes And Modification Thereof (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (2)

Family

ID=32325847

Family Applications (1)

Country Status (5)

Cited By (40)

Families Citing this family (45)

Family Cites Families (58)

• 2002
  • 2002-11-27 US US10/307,276 patent/US7388079B2/en not_active Expired - Lifetime
• 2003
  • 2003-11-18 EP EP03786812.2A patent/EP1569691B1/en not_active Expired - Lifetime
  • 2003-11-18 AU AU2003295614A patent/AU2003295614A1/en not_active Abandoned
  • 2003-11-18 WO PCT/US2003/036870 patent/WO2004050016A2/en not_active Ceased
  • 2003-11-18 JP JP2004557217A patent/JP4773097B2/ja not_active Expired - Fee Related
• 2007
  • 2007-08-14 US US11/893,281 patent/US20080051564A1/en not_active Abandoned
• 2008
  • 2008-05-01 US US12/150,983 patent/US8858950B2/en not_active Expired - Lifetime
• 2011
  • 2011-02-07 JP JP2011023913A patent/JP5981688B2/ja not_active Expired - Fee Related
• 2016
  • 2016-01-28 JP JP2016014310A patent/JP2016155803A/ja active Pending

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events